The effect of targeted therapy on overall survival in advanced renal cancer: A study of the national surveillance epidemiology and end results registry database

Clinical Genitourinary Cancer

Volumn 12, Issue 2, 2014, Pages 124-129

  Vaishampayan, Ulka ^a   Vankayala, Hema ^a   Vigneau, Fawn D ^a   Quarshie, William ^a   Dickow, Brenda ^a   Chalasani, Supraja ^a   Schwartz, Kendra ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Kidney cancer; Nephrectomy; Outcomes; Racial disparity; SEER database

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEALTH CARE ACCESS; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTIVARIATE ANALYSIS; NEGRO; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RACE DIFFERENCE; SURVIVAL TIME; YOUNG ADULT;

KIDNEY CANCER; NEPHRECTOMY; OUTCOMES; RACIAL DISPARITY; SEER DATABASE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM;

EID: 84896395550     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.09.007     Document Type: Article

References (19)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30.
2. A. Jemal, R. Siegel, and J. Xu et al. Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300.
3. G. Fyfe, R.I. Fisher, and S.A. Rosenberg et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 1995 688 696.
4. D.F. McDermott, M.M. Regan, and J.I. Clark et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 2005 133 141.
5. B. Escudier, T. Eisen, and W.M. Stadler et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134.
6. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124.
7. C.N. Sternberg, I.D. Davis, and J. Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068.
8. G. Hudes, M. Carducci, and P. Tomczak et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281.
9. R.J. Motzer, B. Escudier, and S. Oudard et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456.
10. R.T. Tripathi, L.K. Heilbrun, and V. Jain et al. Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma Urology 68 2006 296 301.
11. U.N. Vaishampayan, H. Do, and M. Hussain et al. Racial disparity in incidence patterns and outcome of kidney cancer Urology 62 2003 1012 1017.
12. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659.
13. G.H. Mickisch, A. Garin, and H. van Poppel et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970.
14. A.C. Small, C.K. Tsao, and E.L. Moshier et al. Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States World J Urol 31 2013 1211 1217.
15. D.Y. Heng, K.N. Chi, and N. Murray et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer Cancer 115 2009 776 783.
16. M. Warren, P.M. Venner, and S. North et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment Can Urol Assoc J 3 2009 281 289.
17. D. Shek, B. Tomlinson, and M. Brown et al. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients Clin Genitourin Cancer 10 2012 93 98.
18. D.Y. Heng, W. Xie, and M.M. Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799.
19. R.J. Motzer, J. Bacik, and L.H. Schwartz et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 2004 454 463